Societal CDMO, Inc. (SCTL)
| Market Cap | 116.26M |
| Revenue (ttm) | 94.64M |
| Net Income (ttm) | -13.27M |
| Shares Out | 105.69M |
| EPS (ttm) | -0.14 |
| PE Ratio | n/a |
| Forward PE | 18.25 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 512,703 |
| Open | 1.090 |
| Previous Close | 1.090 |
| Day's Range | 1.090 - 1.100 |
| 52-Week Range | 0.260 - 1.280 |
| Beta | 1.58 |
| Analysts | Buy |
| Price Target | 1.80 (+63.64%) |
| Earnings Date | May 8, 2024 |
About SCTL
Societal CDMO, Inc., a contract development and manufacturing organization, engages in the research and development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecules in the United States and internationally. The company provides end-to-end services, such as formulation development focusing on complex formulations, reformulation, physical characterization, and excipient compatibility; analytical methods development which offers a range of analytical testing capabilities, including product testing... [Read more]
Full Company ProfileFinancial Performance
In 2023, Societal CDMO's revenue was $94.64 million, an increase of 4.90% compared to the previous year's $90.21 million. Losses were -$13.27 million, -33.23% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for SCTL stock is "Buy." The 12-month stock price forecast is $1.8, which is an increase of 63.64% from the latest price.
News
CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.
CLEARWATER, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- CoreRx, Inc. (“CoreRx”) today announced that it has completed its acquisition of Societal CDMO, Inc. (“Societal CDMO”) (Nasdaq: SCTL), a contract d...
SOCIETAL CDMO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Societal CDMO, Inc. - SCTL
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Societal CDMO, I...
SCTL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Societal CDMO, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Societal CDMO, Inc. (NASDAQ: SCTL) to CoreRx, Inc. for $1.10 per share in cash is fair to...
Societal CDMO Enters Into Definitive Agreement to be Acquired by CoreRx, Inc.
Societal CDMO to be Acquired by CoreRx, Inc. to Create an Enhanced CDMO with Broad Capabilities Spanning Early-Stage Formulation Development through Commercial Manufacturing and Packaging
Societal CDMO and Benuvia Sign Co-Marketing Agreement Designed to Promote Complementary CDMO and API Manufacturing Services to Drug Developers
Agreement Broadly Applicable to All Therapeutic Areas with Specific Focus on the Growing Psychedelic and Cannabinoid Drug Development Markets
Societal CDMO Reports Inducement Grants for New Staff
SAN DIEGO and GAINESVILLE, Ga., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASDAQ: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving...
Societal CDMO Reports Third Quarter 2023 Financial Results
Recorded Q3 Revenue of $23.6 Million Signed Multiple New Business Agreements with New and Existing Customers Closed Public Offering Raising Gross Proceeds of Approximately $8.3 Million Initiated Corpo...
Societal CDMO to Report Financial Results for Third Quarter 2023 on November 8, 2023
Webcast Scheduled for Wednesday, November 8, 2023, at 4:30 p.m. Eastern Webcast Scheduled for Wednesday, November 8, 2023, at 4:30 p.m. Eastern
Societal CDMO to Participate in RBC Capital Markets Virtual CDMO Conference
SAN DIEGO and GAINESVILLE, Ga., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (CDMO) dedic...
Societal CDMO Announces Corporate Restructuring
Strategic Realignment Designed to Right Size Organization to Address Macro Pharma Market Financing Challenges and Increase Operational Efficiency in Areas of Historical Strength Strategic Realignment ...
Societal CDMO Secures Project Expansion Agreements With Several Existing Customers
Additional Work Across Facilities in California and Georgia to Include Analytical Method Development and Validation, Dissolution Testing, and Manufacturing of Prototype, Surrogate, and Engineering Bat...
Societal CDMO Announces Closing of $8.3 Million Public Offering of Common Stock
SAN DIEGO and GAINESVILLE, Ga., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (“CDMO”) dedicated to solving co...
Societal CDMO Announces Pricing of $8.3 Million Public Offering of Common Stock
SAN DIEGO and GAINESVILLE, Ga., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (“CDMO”) dedicated to solving co...
Societal CDMO Announces Appointment of Matt Arens to Board of Directors
Experienced Health Care Industry Investor with Track Record of Identifying Innovative Life Science Companies with High Growth Potential Experienced Health Care Industry Investor with Track Record of I...
Societal CDMO Announces Proposed Public Offering of Common Stock
SAN DIEGO and GAINESVILLE, Ga., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (“CDMO”) dedicated to solving co...
Societal CDMO Reports Second Quarter 2023 Financial Results
Recorded Q2 Revenue of $21.8 Million Signed Multiple New Business Agreements with New and Existing Customers Secured Schedule 1 Controlled Substance Manufacturing License from Drug Enforcement Agency;...
Societal CDMO Reschedules Second Quarter 2023 Financial Results Reporting to August 14, 2023
SAN DIEGO and GAINESVILLE, Ga., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicate...
Societal CDMO to Report Financial Results for Second Quarter 2023 on August 9, 2023
Webcast Scheduled for Wednesday, August 9, 2023, at 4:30 p.m. Eastern Webcast Scheduled for Wednesday, August 9, 2023, at 4:30 p.m. Eastern
Societal CDMO Announces Expansion of Controlled Substance Manufacturing Capabilities to Address Expanding Psychedelic Drug Development Market
Company Secures Schedule 1 Controlled Substance Manufacturing License from Drug Enforcement Agency, Expands on 25 Years of Manufacturing of Schedule 2 Products
Societal CDMO Selected by Spinnaker Biosciences to Provide CDMO Services to Support Clinical Development of Novel Therapeutic Candidate
Activities will be Conducted at Societal CDMO's San Diego Facility and Span Analytic Method Transfer, Process Development, and CGMP Manufacturing Activities will be Conducted at Societal CDMO's San Di...
Societal CDMO Signs Master Service Agreement With CivicaScript to Provide CDMO Services
Scope of Work Spans Full Range of Services including Analytical Method Transfer, Formulation Development, Process Development, and Clinical Trial Material Batch Manufacturing Scope of Work Spans Full ...
Societal CDMO Enters Agreement With Atossa Therapeutics to Provide Clinical Trial Services (CTS) for Innovative Selective Estrogen Receptor Modulator
CTS Activities will Focus on Analytic Method Transfer, Manufacturing of R&D Engineering Batches, and Stability Studies to Support Planned Clinical Trials of Atossa's Proprietary Oral (Z)-endoxifen For...
Societal CDMO Reports First Quarter 2023 Financial Results
Recorded Q1 Revenue of $21.5 Million Signed Multiple New Business Agreements with New and Existing Customers Granted FDA Approval for Manufacture of First Commercial Tablet Product Company to Host Web...
Societal CDMO to Participate in RBC Capital Markets Global Healthcare Conference
SAN DIEGO and GAINESVILLE, Ga., May 09, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated...
Societal CDMO Selected by Xequel Bio to Provide CDMO Services to Support Ongoing Clinical Development of iNexin™
Activities Focused on Xequel's Ophthalmic Solution Containing aCT1 Peptide, Being Developed for the Treatment of Persistent Corneal Epithelial Defect and Recurrent Corneal Erosions Activities Focused ...